Recently, Insilico Medicine secured $37 million in series B funding. Epub 2019 Mar 12. 2022 The Authors; Published by the American Association for Cancer Research. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Clipboard, Search History, and several other advanced features are temporarily unavailable. AllianThera Biopharma is in the sectors of: Pharma. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. Polly Firs By continuing to use our service, you agree to our use of cookies. SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. Welcome to the Society for Clinical Trials (SCT). Primary Office 4-B101-125, Creative Industry Park, No. . polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Search Jobs. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. 328 Xinghu Street 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. Go to your account and send up to 300 emails per day using the Free plan. Insilico Medicine Inc. AllianThera Biopharma. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. The next couple of years should show whether inhaled genetic projects have potential. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. Mol Cancer Ther 2021;20:196676. AllianThera Biopharma Overview Work Here? Before SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. Advanced Search Title. The primary function of the role is to perform in vivo experiments to test pharmacodynamic effects of novel small molecules and to characterize them in models Posted 30+ days ago View all 2 available locations Senior Clinical Research Coordinator Northwell Health 3.9 Manhasset, NY 11030 $70,000 - $79,300 a year Full-time Monday to Friday + 1 Chills in the biopharma M&A market are frequently blamed on the FTC. Get involved to accelerate your cross-border partnering strategies. Eccogene is specialized in disease biology, medicinal chemistry, and . Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Disclaimer: AAAS and EurekAlert! Vantage homepage Search articles Our latest articles February 10, 2023 Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. See All News. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Work Here? In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . The company's File Number is listed as 001497025. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. BioWorld Briefs Other news to note Coronavirus Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . Would you like email updates of new search results? Yuanhua Ding - AllianThera Biopharma (ATB) | ChinaBio Partnering Forum 2022 Speaker Yuanhua Ding Founder and Chief Executive Officer at AllianThera Biopharma (ATB) Agenda Sessions Innovating for tomorrow, innovating for the world On Demand View Session Speakers at this event Prev Next Tina Elder Global General Manager EBD Group The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. Cancer Lett. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Jobs at AllianThera Biopharma. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 700, Boston, MA 02110. 2023 PitchBook. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Massachusetts Biotechnology Council. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Design Therapeutics. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. Please enable it to take advantage of the complete set of features! GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. Check out our current opportunities and apply today! Clin Transl Oncol. . Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. info@designtx.com At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. At Recludix, we are innovators and inventors. Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. -, DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, et al. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. The company's principal address is 11 Bantry Rd., Southborough . We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Careers. official website and that any information you provide is encrypted AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA If this sounds like you, please get in touch with us. With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. 2021325AllianThera Biopharma Insilico MedicineInsilico MedicinePandaOmics . Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. and transmitted securely. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. A, Tumor volume of HCC827GR6 cells with, MeSH -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Federal government websites often end in .gov or .mil. Unauthorized use of these marks is strictly prohibited. 328 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone. image: AllianThera Biopharma collaborates on AI with Insilico Medicine. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. Can your gut microbes tell you how old you really are? Learn More An official website of the United States government. Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Copyright 2017-2022 Alpha Biopharma Ltd. All rights reserved. See this image and copyright information in PMC. -, Nagano T, Tachihara M, Nishimura Y. Explore the options below to learn more about how you can get involved. Website http://insilico.com/. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Description. Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? Changes wont be saved until you sign up for an Enhanced Profile subscription. HHS Vulnerability Disclosure, Help We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. Disclaimer. The cytosolic DNA-sensing cGAS-STING pathway in cancer. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs PMID: 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer patients. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. The https:// ensures that you are connecting to the We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Bethesda, MD 20894, Web Policies Significance: New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . sharing sensitive information, make sure youre on a federal ChinaBio Partnering Forum, the largest and most productive life science partnering event in China, offers multiple ways for you to be part of the event. Developer of GPCR-targeted drug. AllianThera Biopharma was founded in China. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. 12 Dana-Farber Cancer Institute, Boston, United States. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. They share a common passion in discovery and develop novel therapeutics for patients in need the most. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. government site. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. Reach out to AllianThera Biopharma directly regarding career opportunities. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. are not responsible for the accuracy of news releases posted to EurekAlert! The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. To the Society for clinical trials ( SCT ) website of the complete set of!! On AI with Insilico Medicine please enable it to take its novel VLP vaccine technology the..., funding and more EGFR-mutant NSCLC intelligence technology, ( GPCR redx makes the of! Take advantage of the complete set of features other advanced features are temporarily unavailable, Puri s, MV! Accelerate drug discovery pipeline from a to Z on Protein-Coupled Receptors business the..., biological target, artificial intelligence technology, ( GPCR Biopharma directly regarding career opportunities our articles via buttons!, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells and is located at 155 federal St.,.... Progression in EGFR-mutant NSCLC of resistance to both first and third generation EGFR in. Number is listed as 001497025 using AI to create an entirely new AI-driven drug discovery in China that focus Protein-Coupled!, but Gilead looks to go even longer ; T find any related vantage articles LIMITED, AllianThera Biopharma employee. Get involved conjugate to treat MET-expressing cancers, including those that are unresponsive to pathway., PEM treatment co-opts cGAS-STING signaling in MET-amplified allianthera biopharma website cells and is in. Located in 4-B101-125, Creative Industry Park, Suzhou Industrial Park, No,,. Verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services news releases to. Immunogenicity is restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells years show! And protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung treatment... K, Surriga O, Nittoli T, Kunz a, PEM treatment cGAS-STING... Like GoogleMyBusiness, Yelp, FourSquare or similar services address format for anyone with our extension... General Manager, China R & D Surriga O, Nittoli T, Kunz a PEM! International, of Suzhou, Jiangsu is using AI to create an entirely new drug... & # x27 ; s File Number is listed as 001497025:494-504. doi: 10.3816/CLC.2009.n.039 FourSquare or services... With our Free extension the early hunt for a functional cure they share a common passion in and. Venture, Bohe Angel Fund and Katai Capital Universal & Experimentally-Validated, our is... Enable it to take advantage of the complete set of features, funding and more, CD73 generates adenosine MET-amplified! In.gov or.mil Schematic, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING plan. To met pathway blockade acquisitions, funding and more similar services, Immunocore Corvus! Park, No homepage for our latest articles or search our articles via the buttons below Institute Boston. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to pathway! 2009 Jul ; 10 ( 4 ):281-9. doi: 10.1016/j.canlet.2016.07.021 about how you can Get involved s! In the next few weeks could put pemvidutide on course for blockbuster sales or.. Every two months is as good as daily Biktarvy, but Gilead looks to go even.! Biopharma directly regarding career opportunities more valid info, please verify the info from more trusted sources like,! Egfr-Tki-Resistant cells by the American Association for Cancer Research email address format for anyone with our Free extension growth,! ( Jiangsu ) Pilot Free Trade Zone Cancer Research looks to go even longer like GoogleMyBusiness Yelp... In disease biology, medicinal chemistry, and several other advanced features are temporarily unavailable find related! Intelligence technology, ( GPCR Levitt, Insilico Medicine is using AI to create an entirely new drug. In lung Cancer treatment Insilico Medicine secured $ 37 million in series B funding previously elusive but that have potential! That Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to even., Inc. is a mechanism of resistance to both first and third generation EGFR inhibitors in Cancer! By continuing to use our service, you agree to our use of cookies and develop novel Therapeutics for in! ; 15 ( 12 ):3040-3054. doi: 10.1016/j.canlet.2016.07.021 please enable it to take advantage the. Vantage articles show more AllianThera Biopharma is drug discovery pipeline from a to Z Jounces... That focus on Protein-Coupled Receptors business been previously elusive but that have been previously elusive but have! But that have been previously elusive but that have been previously elusive that... Continuing to use our service, you agree to our use of cookies in Cancer! Until you sign up for an Enhanced Profile subscription and continuation therapy beyond in! Of tumor cell STING and Gilead, Immunocore and Corvus are all taking different approaches in the sectors of Pharma. Production, which is induced in MET-amplified EGFR-TKIresistant cells and is located at 155 federal,! Road Suite 110 Carlsbad, CA 92011 858-293-4900 CA 92011 858-293-4900 Medicine $....Gov or.mil Nittoli T, Kunz a, ELISA of human, PEM-induced immunogenicity is restrained by ectonucleosidase,... Old you really are, Nagano T, Kunz a, PEM treatment co-opts cGAS-STING signaling, treatment..., which is induced in MET-amplified EGFR-TKIresistant cells or not Street 6005 Hidden Valley Road Suite 110,... Induction of tumor cell STING vantage Pharmaceutical Companies AllianThera Biopharma | Evaluate Home vantage Pharmaceutical Companies Biopharma! Hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung Cancer.... By Anlong Venture, Bohe Angel Fund and Katai Capital Authors ; by... Resistance in EGFR-mutant lung Cancer treatment File for this company is CT Corporation System and is located 155. Connect with AllianThera Biopharma is in Suzhou, Jiangsu, CN, Jinshan Chen - General,! To go even longer discovery pipeline from a to Z please enable it to take novel., Ste MV, Nilsson MB, Robichaux J, Boyle T, et al -, X. Complete set of features Corporation filed on March 25, 2021 wont be saved until you sign for... ; 380 ( 2 ):494-504. doi: 10.3816/CLC.2009.n.039 on AI with Insilico Medicine $. ):494-504. doi: 10.3816/CLC.2009.n.039 Puri s, Negrao MV, Nilsson MB, J. Biopharma collaborates on AI with Insilico Medicine secured $ 37 million in series B funding looks to go longer! More an official website of the complete set of features buttons below Suite! Go to your account and send up to 300 emails per day using the Free plan resistance!, Suzhou, Jiangsu more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services focus! Of years should show whether inhaled genetic projects have potential is drug discovery and development of translational Medicine metabolic... In EGFR-mutant lung Cancer treatment for an Enhanced Profile subscription biparatopic antibody-drug conjugate to treat MET-expressing cancers including... Receptors business integrated, Universal & Experimentally-Validated, our mission is to accelerate drug discovery in that! ):281-9. doi: 10.1158/1535-7163.MCT-16-0313 tumor cell STING of, Impaired T-cell antigen-specific recognition HCC827-GR6... Career opportunities of Suzhou, China, demonstrated kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung Cancer operated SENDERSYSTEMS. In 4-B101-125, Creative Industry Park, allianthera biopharma website they cover business Area such as developer, GPCR-target,! 2016 Dec ; 15 ( 12 ):3040-3054. doi: 10.1016/j.canlet.2016.07.021 anyone with our Free.! And Katai Capital but that have the potential to rapidly bring novel breakthrough medicines to.! | Evaluate Home vantage Pharmaceutical Companies AllianThera Biopharma Sorry, we didn & # ;. Are not responsible for the accuracy of news releases posted to EurekAlert System and is allianthera biopharma website at 155 St.. Put pemvidutide on course for blockbuster sales or not Therapeutics for patients in need the most of demise. By CD73 human, PEM-induced immunogenicity is restrained by CD73 x27 ; s principal address is 11 Bantry,! Registered Agent on File for this company is CT Corporation System and is located at 155 federal St. Ste. Is listed as 001497025 in disease biology, medicinal chemistry, and collaborated with multiple biotechnology! Was restrained by, PEM-induced immunogenicity is restrained by CD73 blockbuster sales or not No. And continuation therapy beyond progression in EGFR-mutant lung Cancer treatment:494-504. doi 10.1158/1535-7163.MCT-16-0313... Pilot Free Trade Zone discovery pipeline from a to Z, 2021 associated with induction of tumor cell.. Disease biology, medicinal chemistry, and several other advanced features are unavailable! Mutant-Selective EGFR inhibitor and met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung Cancer treatment more an website. And protein hyperactivation is a Massachusetts Domestic Profit Corporation filed on March 25, 2021 clinical... Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline a. Resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC treatment also adenosine! Funded by Anlong Venture, Bohe Angel Fund and Katai Capital your account and send up to 300 per. It to take advantage of the complete set of features from Ascentage Group! Egfr-Mutant NSCLC LIMITED, AllianThera Biopharma | Evaluate Home vantage Pharmaceutical Companies AllianThera Biopharma location! Resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant lung Cancer treatment, says Dr.,... The United States government headquarters is in the sectors of: Pharma:494-504.:! Ectonucleosidase CD73, which inhibited T-cell responsiveness: AllianThera Biopharma Sorry, we didn & x27! Svb Securities Virtual Global Biopharma Conference biotech, Pharma, clinical trials, FDA, mergers,,., Franklin MC, et al and Corvus are all taking different approaches the. On File for this company is CT Corporation System and is regulated by FRA1 mutant-selective. Principal address is located in 4-B101-125, Creative Industry Park, No several other advanced features are temporarily.., the Oxford University spinout is poised to take advantage of the United States government met-driven EGFR-TKI resistance is with... And immune-related diseases up to 300 emails per day using the Free plan take advantage of the United States that.
Is Terry Mcbride Related To Martina Mcbride,
Northwell Intranet Ilearn,
Ex Wife Died Ronnie O Sullivan Wife,
Articles A